Compare 3M Company (MMM) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Viatris Inc — how do they compare? 3M Company trades at $170.3 (market cap $82.99B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: 3M Company is far larger — about 4.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| MMM | VTRS | |
|---|---|---|
Market Cap | $82.99B | $19.79B |
Sector | Industrials | Health |
52-Week High | $174.61 | $17.39 |
52-Week Low | $141.10 | $8.74 |
Enterprise Value | $91.39B | $32.00B |
Dividend Yield | 1.96% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) surged 6.83% to $170.76 following strong Q2 2026 earnings that beat expectations, with the company raising full-year guidance. Technical indicators show a bullish trend with support at $158 and resistance at $161. Fundamentally, the company demonstrates robust profitability with 39.71% gross margins and 72.14% ROE, though revenue has declined from 2022 peaks. Recent news highlights operational improvements and growth in Safety & Industrial and Transport & Electronics segments.
The outlook is positive with earnings momentum and raised guidance, but risks include litigation liabilities and macroeconomic headwinds. Analyst consensus is mixed with 48% buy ratings but a $149.75 price target below current levels, suggesting limited near-term upside despite strong operational performance.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
